Randomized, Double-Blind, Crossover, Comparator Pilot Study of DFN-11 Injection (Strength A vs. Strength B) for Rapidly Escalating Migraine

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jun 2017 Primary endpoint (The proportion of subjects reporting Pain freedom at 60 minutes post-treatment according to the subject eDiary entries) has not been met as per the results presented at the 59th Annual Scientific Meeting of the American Headache Society.
11 Jun 2017 Results presented at the 59th Annual Scientific Meeting of the American Headache Society
07 Jun 2017 According to a Promius Pharma media release data from this study will be presented at the 59th Annual Scientific Meeting of the American Headache Society (AHS).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com